📰 GOSS Latest News

Last Updated: 2026.04.07 13:46:51
Recent Headlines
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Gossamer Bio, Inc. of Class Action Lawsuit and Upcoming Deadlines – GOSS
GlobeNewsWire 2026-04-07 1:46 PM
GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Overstated Trial Prospects: Levi & Korsinsky
BusinessWire 2026-04-07 8:00 PM
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Gossamer Bio, Inc. (GOSS) Shareholders To Inquire About Securities Fraud Class Action
BusinessWire 2026-04-07 4:00 PM
Law Offices of Frank R. Cruz Encourages Gossamer Bio, Inc. (GOSS) Shareholders To Inquire About Securities Fraud Class Action
BusinessWire 2026-04-06 4:07 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
PRNewswire 2026-03-26 2:00 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Gossamer Bio, Inc. – GOSS
GlobeNewsWire 2026-03-24 9:33 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
PRNewswire 2026-02-26 8:18 PM
Gossamer Bio, Inc. (GOSS) Discusses Topline Results of PROSERA Phase 3 Study in Pulmonary Arterial Hypertension - Slideshow
SeekingAlpha 2026-02-24 4:32 PM
Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension
BusinessWire 2026-02-23 1:00 PM